MedTrace Logo

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL

NCT05109520 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 867

Last updated 2022-08-30

No results posted yet for this study

Summary

Retrospective multicenter study analyzing data gathered during the FUTURE study (S59342) to assess the effect of using Insulin Glargine 300 U/mL (Gla-300) on measures of diabetes control and quality of life.

Of the FUTURE participants, data about the type of insulin the participants used will be gathered. On the basis of these data participants will be divided in two groups (control or investigational).

Change in glycemic control and quality of life from before to after the switch to Gla-300 (investigational group) will be compared to the change of glycemic control and quality of life of the FUTURE participants who did not switch to Gla-300 (control group).

The FUTURE study was a 24-month during multicenter observational cohort study analyzing data on the use of the Abbott Freestyle Libre in people with diabetes. Data were gathered during standard clinical follow-up, and from questionnaires that were presented to the participants at defined time points.

Conditions

Interventions

DRUG

Insulin Glargine 300 UNT/ML [Toujeo]

Switch during standard routine care to Gla-300.

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • Onze Lieve Vrouw Hospital

    collaborator OTHER

  • prof dr Pieter Gillard

    lead OTHER

Principal Investigators

  • Pieter Gillard, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-08
Primary Completion
2021-10-14
Completion
2021-10-14

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05109520 on ClinicalTrials.gov